Navigation Links
Bioniche Represented at House of Commons Sub-Committee on Food Safety
Date:5/28/2009

    Company seeking endorsement of programs to reduce the risk of
    E. coli O157 contamination of food and water

BELLEVILLE, ON, May 28 /PRNewswire-FirstCall/ - Bioniche Life Sciences Inc. (TSX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today announced that it made representation at the House of Commons Sub-committee on Food Safety yesterday. This was an opportunity for the Company to create additional awareness of its on-farm/pre-harvest intervention to reduce the prevalence of the deadly E. coli O157 bacterium, and to seek further support for vaccination programs.

"Bioniche has proposed that a Government of Canada program be established that encourages adoption of our E. coli O157 cattle vaccine, the only registered vaccine of its kind in the world," said Rick Culbert, President of Bioniche Food Safety. "Such an initiative would position Canada as a global leader in food safety, preserve customer confidence in Canadian agricultural products and bolster public health."

The House of Commons Sub-committee on Food Safety was established following last year's Listeriosis outbreak in Canada. Like Listeriosis, E. coli O157 can be fatal to humans who become infected. An estimated 100,000 cases of human infection with the E. coli O157:H7 organism are reported each year in North America. Two to seven per cent of those people develop haemolytic uremic syndrome (HUS), a disease characterized by kidney failure (in recent outbreaks, this percentage has risen to as high as 16%). Five percent of HUS patients die, many of them children and senior citizens, whose kidneys are more sensitive to damage.

Cattle are the primary carriers of E. coli O157, but the organism, which makes people ill, does not have the same effect on cattle. When people come in contact with contaminated food or water, they can become infected. The Bioniche E. coli vaccine - trademarked Econiche - has been proven in field studies to reduce colonization of cows by O157 and to reduce the amount of the bacteria shed in their manure, thus decreasing the number of bacteria to which humans may be exposed.

On-farm interventions to reduce the shedding of E. coli O157 by cattle, such as vaccination of cattle with Econiche, have the potential to reduce food and water contamination and the consequences associated with human infection with the deadly bacteria. Clinical trials conducted with Econiche have shown a significant reduction in the amount of E. coli shed in the manure of vaccinated cows.

It appears to Bioniche that most Canadian cattlemen are willing to administer the vaccine, but cannot afford to incur the expense of the vaccine without receiving an offsetting increase in revenue. At the same time, cattle producers believe that they receive no immediate or direct benefit for spending money to vaccinate their herds against E. coli O157. Bioniche is seeking the support of government to provide initial funding to encourage adoption, given that E. coli O157 poses a serious risk to human health.

Econiche is manufactured in the Bioniche production facility in Belleville, Ontario, where a $25-million expansion is taking place, supported by the Ontario and Canadian governments. Vaccine supply will be limited during this manufacturing expansion period.

About Econiche

Econiche received international recognition in September 2007 by the Animal Pharm Industry Excellence Awards as the best new veterinary product for livestock globally. The vaccine has been developed by a strategic alliance formed in 2000 between the University of British Columbia (UBC), the Alberta Research Council (ARC), the University of Saskatchewan's Vaccine & Infectious Disease Organization (VIDO), and Bioniche, which holds the rights for worldwide commercialization of the vaccine. The vaccine prevents the E. coli O157 bacteria from attaching to the intestines of vaccinated cattle, thereby reducing their reproduction within the animal, and reducing the amount of bacteria that can be released through cattle manure in the environment. More than 30,000 cattle have been involved in clinical testing of the vaccine over the past six years.

Several articles have been published in peer-reviewed journals about Econiche. Two articles were published in the Journal of Food Protection in November, 2007 related to field challenge studies conducted at the University of Nebraska-Lincoln involving close to 900 animals in 2002 and 2003. Among the findings by researchers Dr. David Smith and Dr. Rod Moxley et al: Vaccinating a majority of cattle within a pen resulted in a significant protective effect to unvaccinated cattle in the same pen. This effect is called "herd immunity". Another article was published in the Vol. 5, Number 5, 2008 issue of Foodborne Pathogens and Disease outlining the outcome of a clinical vaccine trial of commercially fed cattle that tested the effect of a two-dose regimen of Econiche against type III secreted proteins of enterohemorrhagic Escherichia coli (E. coli) O157:H7 on the probability of detecting the organism on environmental sampling devices. A fourth article appeared in Volume 6, Number 2, 2009 of the Journal of Food Protection (March, 2009) summarizing the results of a large-scale commercial beef feedlot study with Econiche, whereby researchers a David R. Smith, Rodney A. Moxley et al concluded that a two-dose vaccine regimen effectively reduced the probability for E. coli O157:H7 colonization of the terminal rectal mucosa (TRM) of commercially fed cattle at harvest. In this study, vaccinated cattle were 92% less likely to be colonized with E. coli O157:H7 than non-vaccinated cattle. This was the second published study demonstrating more than 90% effectiveness of the Bioniche vaccine against colonization.

About Bioniche Life Sciences Inc.

Bioniche Life Sciences Inc. is a research-based, technology-driven Canadian biopharmaceutical company focused on the discovery, development, manufacturing, and marketing of proprietary products for human and animal health markets worldwide. The fully-integrated company employs approximately 200 skilled personnel and has three operating divisions: Human Health, Animal Health, and Food Safety. The Company's primary goal is to develop proprietary cancer therapies supported by revenues from marketed products in human and animal health. Bioniche has been named one of the Top 50 Best Small and Medium-Sized Employers in Canada for 2009. For more information, please visit www.Bioniche.com.

Except for historical information, this news release may contain forward-looking statements that reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.


'/>"/>
SOURCE Bioniche Life Sciences Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Bioniche Phase III Clinical Trial with Urocidin(TM) Progressing Well
2. Bioniche Reports Fiscal 2009 Third Quarter
3. Bioniche Provides a Corporate Update
4. Bioniche Completes Recruitment in First Phase III Clinical Trial with Urocidin(TM)
5. Bioniche Revolving Credit Facility Maturity Date Amended
6. Bioniche Phase II Bladder Cancer Trial Results Published in The Journal of Urology
7. Bioniche Warrants Expiration Date to be Extended
8. Bioniche Reports Fiscal 2009 Second Quarter
9. Bioniche Invited to Participate in Canadian Beef Value Chain Roundtable
10. Bioniche Named One of the Top 50 Best Small and Medium Employers in Canada
11. Bioniche Presents MCC Data at the SIU World Uro-Oncology Update in Santiago, Chile
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ... introduction of an innovative new design of the shoulder pad. The shoulder pad ... comfort while controlling your pain while using cold therapy. By utilizing ice and water ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... drug delivery system that we intend to develop to enable prevention of a ... lead to severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss ...
(Date:10/12/2017)... ... 2017 , ... Leading pediatric oncology experts at Children’s National Health System ... Congress of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired by ... and Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., Chief of ...
(Date:10/12/2017)... ... , ... Health Literacy Innovations (HLI), creator of the Health ... Cancer Patient Education Network (CPEN), an independent professional organization that shares best practices ... , As CPEN’s strategic partner, HLI will help support CPEN members by ...
(Date:10/12/2017)... Washington, D.C. (PRWEB) , ... October 12, 2017 ... ... Company, Cal Dining at the University of California Berkeley, and other leading institutions ... leverages the buying power of institutions to change the way animals are raised ...
Breaking Medicine News(10 mins):
(Date:10/4/2017)... to the Centers for Disease Control and Prevention (CDC), influenza vaccination ... is helping communities across Massachusetts , Connecticut ... flu shots through the end of the month. *Some exclusions ... ... shot is by the end of October, according to the Centers for ...
(Date:10/2/2017)... INDIANAPOLIS , Oct. 2, 2017  Eli Lilly ... its financial results for the third quarter of 2017 ... a conference call on that day with the investment ... performance. The conference call will begin at ... public can access a live webcast of the conference ...
(Date:10/2/2017)... 2, 2017 The Rebound mobile app is poised ... reverse the tide of prescription drug addiction. The app empowers ... intake and stepping down their dosage in a safe, controlled ... December 2017; the first 100,000 people to sign up will ... http://www.rebound-solution.com/ ...
Breaking Medicine Technology: